한글목차

안과용 의약품 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 422억 5,000만 달러에서 2026년에는 452억 4,000만 달러에 이르고, CAGR 7.1%로 성장할 전망입니다. 지난 수년간의 성장에는 고령화 인구 증가, 녹내장 및 백내장 발병률 증가, 안과 진료소 증가, 안과 처방약에 대한 접근성 향상, 병원 약국 네트워크 확대 등이 주요 요인으로 꼽힙니다.

안과용 의약품 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 612억 1,000만 달러에 이르고, CAGR은 7.9%를 나타낼 전망입니다. 예측 기간 동안 성장 요인으로는 지속형 안과 약물 전달의 발전, 눈 건강에 대한 인식 증가, 망막 질환 치료 확대, 신흥국의 의료비 지출 증가, OTC 안과 제품의 보급 확대 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 만성 안질환 유병률 증가, 안구건조증 치료 수요 증가, 복합 안약 채택 증가, 무방부제 제제로의 전환, 안과용 의약품의 온라인 약국 확대 등이 있습니다.

안과 질환의 유병률 증가는 향후 몇 년 동안 안과 의약품 시장의 성장을 견인할 것으로 예측됩니다. 안과 질환이란 눈 또는 관련 구조에 영향을 미쳐 시력 장애 및 기타 눈 관련 합병증을 유발하는 질환이나 상태를 말합니다. 안과용 의약품은 눈이나 시력에 영향을 미치는 질환을 치료하기 위해 사용되는 의약품입니다. 따라서 안과 질환의 유병률 증가는 안과용 의약품 수요를 직접적으로 증가시킵니다. 예를 들어, 2023년 8월 스위스에 본부를 둔 유엔기구인 세계보건기구(WHO)가 발표한 자료에 따르면, 2023년 기준 전 세계 최소 22억 명이 근시 또는 원시로 인한 시각 장애를 앓고 있으며, 그 중 10억 건 이상이 예방 가능하거나 치료되지 않은 상태인 것으로 추정되고 있습니다. 굴절 이상과 백내장이 주요 원인으로 확인되었으며, 각각 36%와 17%의 중재 적용률은 각각 36%와 17%에 불과합니다. 따라서 안과 질환의 유병률 증가는 안과용 의약품 시장 확대에 기여하고 있습니다.

안과 의약품 시장에서 활동하는 주요 기업들은 효과적인 치료 옵션을 제공하기 위해 무방부제 제제(무방부제 라타노프로스트 등) 개발에 주력하고 있습니다. 무방부제 라타노프로스트는 녹내장 등의 증상 관리에 사용되는 라타노프로스트 제제입니다. 예를 들어, 2023년 9월 안과 제품 상용화에 주력하는 미국 제약사 Thea Pharma는 원발성 개방각 녹내장(POAG) 및 안압상승증(OHT) 치료제로 미국에서 최초로 승인된 무방부제 라타노프로스트 제제 '이유제(라타노프로스트 점안액) 0.005%'를 출시했습니다.%'를 출시했습니다. 2022년 12월 FDA 승인을 받은 이유제는 전 세계 6,000만 명 이상의 녹내장 환자들에게 효과적인 치료 옵션을 제공할 수 있게 됐습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Ophthalmic drugs are a category of pharmaceutical medicines used to treat conditions affecting the eyes or vision. These medications are commonly prescribed for managing eye infections and other ocular disorders.

The primary types of ophthalmic drugs include prescription medications and over-the-counter drugs. Prescription ophthalmic drugs are those that can be obtained only with a prescription from a licensed physician or medical practitioner. The different classes include anti-allergy, anti-inflammatory, anti-glaucoma, and other drug classes used to treat conditions such as dry eye, eye allergies, glaucoma, eye infections, retinal disorders, uveitis, and other eye diseases. These drugs are available in various dosage forms, including liquid ophthalmic formulations, solid ophthalmic forms, semisolid ophthalmic forms, and multicompartment drug delivery systems. They are distributed through multiple channels, including hospital pharmacies, drug stores, and online pharmacies.

Tariffs have moderately impacted the ophthalmic drugs market by increasing the cost of imported active pharmaceutical ingredients, packaging materials, and specialized drug delivery components, leading to higher production and pricing pressures. Prescription drug segments such as antiglaucoma agents and retinal disorder treatments, along with regions dependent on cross-border pharmaceutical supply chains including asia-pacific and europe, are most affected. However, tariffs have also encouraged local manufacturing, regional sourcing of raw materials, and investments in domestic pharmaceutical production, supporting long-term supply chain resilience and market stability.

The ophthalmic drugs market research report is one of a series of new reports from The Business Research Company that provides ophthalmic drugs market statistics, including ophthalmic drugs industry global market size, regional shares, competitors with a ophthalmic drugs market share, detailed ophthalmic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the ophthalmic drugs industry. This ophthalmic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ophthalmic drugs market size has grown strongly in recent years. It will grow from $42.25 billion in 2025 to $45.24 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increasing aging population, rising incidence of glaucoma and cataract, growth in ophthalmology clinics, improved access to prescription eye medicines, expansion of hospital pharmacy networks.

The ophthalmic drugs market size is expected to see strong growth in the next few years. It will grow to $61.21 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to advancement in sustained-release ocular drug delivery, increasing awareness of eye health, growth in retinal disorder treatments, rising healthcare expenditure in emerging economies, expanding otc ophthalmic product adoption. Major trends in the forecast period include rising prevalence of chronic eye disorders, growing demand for dry eye therapies, increased adoption of combination ophthalmic drugs, shift toward preservative-free formulations, expansion of online pharmacies for eye medications.

The rising prevalence of ophthalmic disorders is anticipated to drive the growth of the ophthalmic drugs market in the coming years. Ophthalmic disorders include diseases or conditions that affect the eyes or related structures, leading to vision impairment and other eye-related complications. Ophthalmic drugs are pharmaceutical products used to treat conditions affecting the eyes or vision; therefore, an increase in the prevalence of ophthalmic disorders directly raises demand for ophthalmic medications. For instance, in August 2023, according to the World Health Organization (WHO), a Switzerland-based United Nations organization, at least 2.2 billion people worldwide were living with near or distance vision impairment in 2023, with more than 1 billion cases being preventable or untreated. Refractive errors and cataracts were identified as the leading causes, with intervention coverage limited to just 36% and 17%, respectively. Thus, the growing prevalence of ophthalmic disorders is contributing to the expansion of the ophthalmic drugs market.

Key companies operating in the ophthalmic drugs market are concentrating on the development of preservative-free formulations, such as preservative-free latanoprost, to offer effective treatment options. Preservative-free latanoprost is a formulation of latanoprost used in the management of conditions such as glaucoma. For example, in September 2023, Thea Pharma, a US-based pharmaceutical company focused on commercializing eye care products, launched Iyuzeh (latanoprost ophthalmic solution) 0.005%, the first preservative-free latanoprost approved in the United States for the treatment of primary open-angle glaucoma (POAG) and ocular hypertension (OHT). Iyuzeh, which received FDA approval in December 2022, provides an effective treatment option for more than 60 million people worldwide affected by glaucoma.

In November 2025, Harrow Inc., a US-based provider of ophthalmic disease management solutions, acquired Melt Pharmaceuticals for an undisclosed amount. Through this acquisition, Harrow seeks to broaden its ophthalmic drug portfolio and enhance its capabilities in procedural sedation by incorporating Melt's non-opioid, non-intravenous sublingual sedation therapies into its wider ophthalmic and outpatient care offerings. Melt Pharmaceuticals is a US-based clinical-stage company developing non-opioid, non-IV oral dissolving tablet sedation therapies for medical procedures in ophthalmology and other outpatient settings.

Major companies operating in the ophthalmic drugs market are AbbVie Inc., Alcon Inc., Bausch & Lomb Incorporated, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Nicox S.A., Johnson & Johnson, Otsuka Pharmaceutical Co. Ltd., Viatris Inc., Akorn Incorporated, GlaxoSmithKline plc, Bayer AG, Senju Pharmaceutical Co. Ltd., Aerie Pharmaceuticals Inc., Kala Pharmaceuticals Inc., Aurobindo Pharma Ltd., Eyevance Pharmaceuticals, Acucela Inc., Dompe Farmaceutici S.p.A., Laboratoires Thea

North America was the largest region in the ophthalmic drugs market in 2025. The regions covered in the ophthalmic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ophthalmic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ophthalmic drugs market consists of ophthalmic sales of anti-angiogenic drugs, anti-vascular endothelial growth factor drugs, anti-uveitis drugs, and prostaglandin analogs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ophthalmic Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses ophthalmic drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ophthalmic drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ophthalmic drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Prescription Drugs; Over-The-Counter Drugs
• 2) By Class: Anti-Allergy; Anti-Inflammatory; Anti-Glaucoma; Other Classes
• 3) By Disease: Dry Eye; Eye Allergy; Glaucoma; Eye Infection; Retinal Disorders; Uveitis; Other Diseases
• 4) By Dosage Form: Liquid Ophthalmic Drug Forms; Solid Ophthalmic Drug Forms; Semisolid Ophthalmic Drug Forms; Multicompartment Drug Delivery Systems
• 5) By Distribution Channel: Hospital Pharmacies; Drug Stores; Online Pharmacies
• Subsegments:
• 1) By Prescription Drugs: Antiglaucoma Agents; Anti-inflammatory Drugs; Antibiotics; Antivirals; Corticosteroids; Other Prescription Drugs
• 2) By Over-The-Counter Drugs: Artificial Tears; Allergy Relief Medications; Redness Relievers; Ocular Vitamins And Supplements; Other OTC Drugs
• Companies Mentioned: AbbVie Inc.; Alcon Inc.; Bausch & Lomb Incorporated; F. Hoffmann-La Roche Ltd.; Novartis AG; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Santen Pharmaceutical Co. Ltd.; Sun Pharmaceutical Industries Limited; Teva Pharmaceutical Industries Ltd.; Merck & Co. Inc.; Nicox S.A.; Johnson & Johnson; Otsuka Pharmaceutical Co. Ltd.; Viatris Inc.; Akorn Incorporated; GlaxoSmithKline plc; Bayer AG; Senju Pharmaceutical Co. Ltd.; Aerie Pharmaceuticals Inc.; Kala Pharmaceuticals Inc.; Aurobindo Pharma Ltd.; Eyevance Pharmaceuticals; Acucela Inc.; Dompe Farmaceutici S.p.A.; Laboratoires Thea
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Ophthalmic Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Ophthalmic Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Ophthalmic Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Ophthalmic Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Sustainability, Climate Tech & Circular Economy
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Prevalence Of Chronic Eye Disorders
  • 4.2.2 Growing Demand For Dry Eye Therapies
  • 4.2.3 Increased Adoption Of Combination Ophthalmic Drugs
  • 4.2.4 Shift Toward Preservative-Free Formulations
  • 4.2.5 Expansion Of Online Pharmacies For Eye Medications

5. Ophthalmic Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Ophthalmology Clinics
• 5.3 Ambulatory Surgical Centers
• 5.4 Specialty Eye Care Centers
• 5.5 Retail Pharmacies

6. Ophthalmic Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Ophthalmic Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Ophthalmic Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Ophthalmic Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Ophthalmic Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Ophthalmic Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Ophthalmic Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Ophthalmic Drugs Market Segmentation

• 9.1. Global Ophthalmic Drugs Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Prescription Drugs, Over-The-Counter Drugs
• 9.2. Global Ophthalmic Drugs Market, Segmentation By Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Anti-Allergy, Anti-Inflammatory, Anti-Glaucoma, Other Classes
• 9.3. Global Ophthalmic Drugs Market, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Dry Eye, Eye Allergy, Glaucoma, Eye Infection, Retinal Disorders, Uveitis, Other Diseases
• 9.4. Global Ophthalmic Drugs Market, Segmentation By Dosage Form, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Liquid Ophthalmic Drug Forms, Solid Ophthalmic Drug Forms, Semisolid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems
• 9.5. Global Ophthalmic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Drug Stores, Online Pharmacies
• 9.6. Global Ophthalmic Drugs Market, Sub-Segmentation Of Prescription Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Antiglaucoma Agents, Anti-inflammatory Drugs, Antibiotics, Antivirals, Corticosteroids, Other Prescription Drugs
• 9.7. Global Ophthalmic Drugs Market, Sub-Segmentation Of Over-The-Counter Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Artificial Tears, Allergy Relief Medications, Redness Relievers, Ocular Vitamins And Supplements, Other OTC Drugs

10. Ophthalmic Drugs Market Regional And Country Analysis

• 10.1. Global Ophthalmic Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Ophthalmic Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Ophthalmic Drugs Market

• 11.1. Asia-Pacific Ophthalmic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Ophthalmic Drugs Market

• 12.1. China Ophthalmic Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Ophthalmic Drugs Market

• 13.1. India Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Ophthalmic Drugs Market

• 14.1. Japan Ophthalmic Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Ophthalmic Drugs Market

• 15.1. Australia Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Ophthalmic Drugs Market

• 16.1. Indonesia Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Ophthalmic Drugs Market

• 17.1. South Korea Ophthalmic Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Ophthalmic Drugs Market

• 18.1. Taiwan Ophthalmic Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Ophthalmic Drugs Market

• 19.1. South East Asia Ophthalmic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Ophthalmic Drugs Market

• 20.1. Western Europe Ophthalmic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Ophthalmic Drugs Market

• 21.1. UK Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Ophthalmic Drugs Market

• 22.1. Germany Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Ophthalmic Drugs Market

• 23.1. France Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Ophthalmic Drugs Market

• 24.1. Italy Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Ophthalmic Drugs Market

• 25.1. Spain Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Ophthalmic Drugs Market

• 26.1. Eastern Europe Ophthalmic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Ophthalmic Drugs Market

• 27.1. Russia Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Ophthalmic Drugs Market

• 28.1. North America Ophthalmic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Ophthalmic Drugs Market

• 29.1. USA Ophthalmic Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Ophthalmic Drugs Market

• 30.1. Canada Ophthalmic Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Ophthalmic Drugs Market

• 31.1. South America Ophthalmic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Ophthalmic Drugs Market

• 32.1. Brazil Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Ophthalmic Drugs Market

• 33.1. Middle East Ophthalmic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Ophthalmic Drugs Market

• 34.1. Africa Ophthalmic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Ophthalmic Drugs Market, Segmentation By Type, Segmentation By Class, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Ophthalmic Drugs Market Regulatory and Investment Landscape

36. Ophthalmic Drugs Market Competitive Landscape And Company Profiles

• 36.1. Ophthalmic Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Ophthalmic Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Ophthalmic Drugs Market Company Profiles
  • 36.3.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Alcon Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Bausch & Lomb Incorporated Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

37. Ophthalmic Drugs Market Other Major And Innovative Companies

• Pfizer Inc., Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Nicox S.A., Johnson & Johnson, Otsuka Pharmaceutical Co. Ltd., Viatris Inc., Akorn Incorporated, GlaxoSmithKline plc, Bayer AG, Senju Pharmaceutical Co. Ltd., Aerie Pharmaceuticals Inc.

38. Global Ophthalmic Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Ophthalmic Drugs Market

40. Ophthalmic Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Ophthalmic Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Ophthalmic Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Ophthalmic Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer